Endocrine Abstracts

Low testosterone is associated with an increased prevalence of cardiovascular (CV) disease. Testosterone replacement improves several CV risk factors including lowering cholesterol and may protect against atherogenesis. Macrophage liver X receptor α (LXRα) stimulates cholesterol efflux which is a therapeutic target for the treatment of atherosclerosis. It was therefore proposed that the anti-atherogenic effect of testosterone may be mediated via LXRα. THP-1 macr...

Low testosterone is associated with an increased prevalence of cardiovascular (CV) diseases such as atherosclerosis. Testosterone replacement improves several CV risk factors including lowering cholesterol. Liver X receptor α (LXRα) is present in various cell types such as macrophages where it stimulates cholesterol efflux and this ability means LXRα agonists are a potential therapy for atherosclerosis. It was therefore proposed that testosterone acts to reduce ...

Objectives: Symptomatic hypogonadism is common in obese men with type-2 diabetes (T2DM) and metabolic syndrome (MetS), and is now an independent risk factor for cardiovascular disease. Testosterone replacement therapy (TRT) improves cholesterol metabolism in hypogonadal men with T2DM and/or MetS. We have previously shown that a non-functional androgen receptor (AR) and low levels of circulating testosterone in the testicular feminised (Tfm) mouse is associated with elevated ch...